EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rationale and Design of the PASSIVATE‐CAP Trial: The Preventive Intervention Value of Drug‐Coated Balloons in Vulnerable Coronary Atherosclerotic Plaques

Zhongxiu Chen iD, Junyan Zhang iD, Minggang Zhou, Shichu Liang iD, Yong Chen, Chen Li iD, Hua Wang, Jiafu Wei, Baotao Huang iD, Mian Wang, Yong He iD, PASSIVATE‐CAP trial investigator

Clinical Cardiology · 2026

DOI: 10.1002/clc.70243 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Cardiology, 2026. Verfasst von Zhongxiu Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, West China Hospital of Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Angioplasty, Balloon, Coronary, Cardiac Catheters, Coated Materials, Biocompatible. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Nuo Qi ASCVD Management Innovation Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with acute coronary syndrome (ACS) face a significantly increased risk of cardiovascular events due to vulnerable plaques. However, no clear evidence supports performing preventive percutaneous coronary intervention (PCI) for non‐flow‐limiting vulnerable plaques. To address this gap, the PASSIVATE‐CAP study was designed to investigate the therapeutic potential of drug‐coated balloon (DCB) for treating non‐flow‐limiting vulnerable plaques.

Methods

The PASSIVATE‐CAP study is an investigator‐initiated, prospective, randomized, multicenter, open‐label superiority trial focusing on acute coronary syndrome (ACS) patients with non‐flow‐limiting vulnerable plaques in non‐culprit vessels. In this study, eligible patients will be randomized at a 1:1 ratio into two groups: patients who received guideline‐directed medical therapy (GDMT) and patients who received GDMT combined with a drug‐coated balloon (DCB). The primary endpoint was the minimal lumen area of the target lesion 1 year after randomization. The secondary endpoints encompass a range of factors, including the proportion of patients with vulnerable plaques in the target vessel, fibrous cap thickness, lipid core arc of the target lesion, minimal lumen area of the target vessel, among others. The study has been registered on Clinicaltrials.gov (Identifier: NCT06416813).

Results

The PASSIVATE‐CAP study enrolled its first patient on July 14, 2025, with projected enrollment completion by January 31, 2027. As of December 28, 2025, 6 patients have been enrolled. The anticipated study end date, marking the completion of the follow‐up period, is January 31, 2028.

Conclusions

The PASSIVATE‐CAP study represents the first prospective, randomized, multicenter, open‐label trial designed to explore the therapeutic value of DCB for the treatment of vulnerable plaques within the ACS patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromeAngioplasty, Balloon, CoronaryCardiac CathetersCoated Materials, BiocompatibleCoronary Artery DiseaseCoronary VesselsPercutaneous Coronary InterventionPlaque, AtheroscleroticAgedFemaleHumansMaleMiddle AgedCoronary AngiographyMulticenter Studies as TopicProspective StudiesRandomized Controlled Trials as TopicTreatment OutcomeEquivalence Trials as Topic

Stichwörter der Autor:innen

acute coronary syndromedrug‐coated balloonpercutaneous coronary interventionvulnerable plaque

Substanzen

Coated Materials, Biocompatible

Autor:innen und Institutionen

  • Department of Cardiology, West China Hospital of Sichuan University, Chengdu, China.

ORCID-Profile: Zhongxiu Chen, Junyan Zhang, Shichu Liang, Chen Li, Baotao Huang, Yong He

Förderung

  • the Nuo Qi ASCVD Management Innovation Research Fund

Zitieren

APA

Chen, Z., Zhang, J., Zhou, M., Liang, S., Chen, Y., Li, C., Wang, H., Wei, J., Huang, B., Wang, M., He, Y., & PASSIVATE‐CAP trial investigator (2026). Rationale and Design of the PASSIVATE‐CAP Trial: The Preventive Intervention Value of Drug‐Coated Balloons in Vulnerable Coronary Atherosclerotic Plaques. Clinical Cardiology. https://doi.org/10.1002/clc.70243

Vancouver

Chen Z, Zhang J, Zhou M, Liang S, Chen Y, Li C, et al. Rationale and Design of the PASSIVATE‐CAP Trial: The Preventive Intervention Value of Drug‐Coated Balloons in Vulnerable Coronary Atherosclerotic Plaques. Clinical Cardiology. 2026. doi:10.1002/clc.70243

BibTeX
@article{Chen2026,
  author = {Chen, Zhongxiu and Zhang, Junyan and Zhou, Minggang and Liang, Shichu and Chen, Yong and Li, Chen and Wang, Hua and Wei, Jiafu and Huang, Baotao and Wang, Mian and He, Yong and PASSIVATE‐CAP trial investigator, PASSIVATE‐CAP trial investigator},
  title = {Rationale and Design of the PASSIVATE‐CAP Trial: The Preventive Intervention Value of Drug‐Coated Balloons in Vulnerable Coronary Atherosclerotic Plaques},
  journal = {Clinical Cardiology},
  year = {2026},
  doi = {10.1002/clc.70243}
}
Kostenlos starten →